fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Trifluoperazine

4 general benefit · 4 not a benefit

Trifluoperazine · DIN 00345539 · 1 mg · tablet

General benefitDormant since March 16, 2020 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Trifluoperazine · DIN 00345539 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2020-03-16 · brand TRIFLUOPERAZINE · ATC N05AB06 TRIFLUOPERAZINE · form Tablet · route Oral · ingredients TRIFLUOPERAZINE (TRIFLUOPERAZINE HYDROCHLORIDE) 1 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Trifluoperazine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1340). What the ministry pays, not the patient.

Ministry pays: $0.1340 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00345539)

Source record
DIN 00345539: Trifluoperazine Raw flags: sec3=Y Item: 281608082; group id 508; item number 1341; lccId None; manufacturer id AAP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.1340; ministry $0.1340 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00345539 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2308
Interchangeable products
Stelazine · DIN 01918206 · not recorded
Shortage status: active shortage (reported March 15, 2019, last updated May 14, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00345539
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since March 16, 2020 — choose a marketed DIN from the same-category list.

Trifluoperazine · DIN 00312754 · 2 mg · tablet

General benefitDormant since July 24, 2020 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Trifluoperazine · DIN 00312754 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2020-07-24 · brand TRIFLUOPERAZINE · ATC N05AB06 TRIFLUOPERAZINE · form Tablet · route Oral · ingredients TRIFLUOPERAZINE (TRIFLUOPERAZINE HYDROCHLORIDE) 2 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Trifluoperazine: Formulary list price $0.18 per unit (the source does not state the unit; exact figure $0.1793). What the ministry pays, not the patient.

Ministry pays: $0.1793 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00312754)

Source record
DIN 00312754: Trifluoperazine Raw flags: sec3=Y Item: 281608081; group id 508; item number 1342; lccId None; manufacturer id AAP Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.1793; ministry $0.1793 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00312754 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2210
Interchangeable products
Stelazine · DIN 01918214 · not recorded
Shortage status: active shortage (reported July 7, 2020, last updated May 14, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00312754
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 24, 2020 — choose a marketed DIN from the same-category list.

Trifluoperazine · DIN 00312746 · 5 mg · tablet

General benefitDormant since April 21, 2024 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Trifluoperazine · DIN 00312746 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2024-04-21 · brand TRIFLUOPERAZINE · ATC N05AB06 TRIFLUOPERAZINE · form Tablet · route Oral · ingredients TRIFLUOPERAZINE (TRIFLUOPERAZINE HYDROCHLORIDE) 5 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Trifluoperazine: Formulary list price $0.24 per unit (the source does not state the unit; exact figure $0.2375). What the ministry pays, not the patient.

Ministry pays: $0.2375 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00312746)

Source record
DIN 00312746: Trifluoperazine Raw flags: sec3=Y Item: 281608080; group id 508; item number 1343; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.2375; ministry $0.2375 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00312746 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2209
Interchangeable products
Stelazine · DIN 01918222 · not recorded
Shortage status: active shortage (reported April 20, 2023, last updated July 2, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00312746
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since April 21, 2024 — choose a marketed DIN from the same-category list.

Trifluoperazine · DIN 00326836 · 10 mg · tablet

General benefitDormant since October 6, 2024 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Trifluoperazine · DIN 00326836 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2024-10-06 · brand TRIFLUOPERAZINE · ATC N05AB06 TRIFLUOPERAZINE · form Tablet · route Oral · ingredients TRIFLUOPERAZINE (TRIFLUOPERAZINE HYDROCHLORIDE) 10 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Trifluoperazine: Formulary list price $0.28 per unit (the source does not state the unit; exact figure $0.2846). What the ministry pays, not the patient.

Ministry pays: $0.2846 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00326836)

Source record
DIN 00326836: Trifluoperazine Raw flags: sec3=Y Item: 281608079; group id 508; item number 1344; lccId None; manufacturer id AAP Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2846; ministry $0.2846 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00326836 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2300
Interchangeable products
Stelazine · DIN 01918230 · not recorded
Shortage status: active shortage (reported not recorded, last updated July 2, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00326836
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since October 6, 2024 — choose a marketed DIN from the same-category list.

Stelazine · DIN 01918206 · 1 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-11-30 — choose a marketed DIN from the same-category list.Discontinued November 30, 2000 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-11-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-11-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Stelazine · DIN 01918206 Manufacturer: Smith Kline Beecham Pharma Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2000-11-30 · brand STELAZINE TAB 1MG · ATC N05AB06 TRIFLUOPERAZINE · form Tablet · route Oral · ingredients TRIFLUOPERAZINE (TRIFLUOPERAZINE HYDROCHLORIDE) 1 MG/TAB · company Smithkline beecham pharma division of smithkline beecham inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stelazine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01918206)

Source record
DIN 01918206: Stelazine Raw flags: notABenefit=Y, sec3=Y Item: 281608082; group id 508; item number 1341; lccId None; manufacturer id SMJ Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01918206 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15214
Interchangeable products
Trifluoperazine · DIN 00345539 · $0.1340
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01918206
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 30, 2000 — choose a marketed DIN from the same-category list.

Stelazine · DIN 01918214 · 2 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-10-18 — choose a marketed DIN from the same-category list.Discontinued October 18, 2000 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-10-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-10-18 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Stelazine · DIN 01918214 Manufacturer: Smith Kline Beecham Pharma Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2000-10-18 · brand STELAZINE TAB 2MG · ATC N05AB06 TRIFLUOPERAZINE · form Tablet · route Oral · ingredients TRIFLUOPERAZINE (TRIFLUOPERAZINE HYDROCHLORIDE) 2 MG/TAB · company Smithkline beecham pharma division of smithkline beecham inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stelazine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01918214)

Source record
DIN 01918214: Stelazine Raw flags: notABenefit=Y, sec3=Y Item: 281608081; group id 508; item number 1342; lccId None; manufacturer id SMJ Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01918214 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18890
Interchangeable products
Trifluoperazine · DIN 00312754 · $0.1793
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01918214
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 18, 2000 — choose a marketed DIN from the same-category list.

Stelazine · DIN 01918222 · 5 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-09-28 — choose a marketed DIN from the same-category list.Discontinued September 28, 2000 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-09-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-09-28 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Stelazine · DIN 01918222 Manufacturer: Smith Kline Beecham Pharma Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2000-09-28 · brand STELAZINE TAB 5MG · ATC N05AB06 TRIFLUOPERAZINE · form Tablet · route Oral · ingredients TRIFLUOPERAZINE (TRIFLUOPERAZINE HYDROCHLORIDE) 5 MG/TAB · company Smithkline beecham pharma division of smithkline beecham inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stelazine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01918222)

Source record
DIN 01918222: Stelazine Raw flags: notABenefit=Y, sec3=Y Item: 281608080; group id 508; item number 1343; lccId None; manufacturer id SMJ Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01918222 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15213
Interchangeable products
Trifluoperazine · DIN 00312746 · $0.2375
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01918222
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 28, 2000 — choose a marketed DIN from the same-category list.

Stelazine · DIN 01918230 · 10 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-11-30 — choose a marketed DIN from the same-category list.Discontinued November 30, 2000 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-11-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-11-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Stelazine · DIN 01918230 Manufacturer: Smith Kline Beecham Pharma Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2000-11-30 · brand STELAZINE TAB 10MG · ATC N05AB06 TRIFLUOPERAZINE · form Tablet · route Oral · ingredients TRIFLUOPERAZINE (TRIFLUOPERAZINE HYDROCHLORIDE) 10 MG/TAB · company Smithkline beecham pharma division of smithkline beecham inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stelazine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01918230)

Source record
DIN 01918230: Stelazine Raw flags: notABenefit=Y, sec3=Y Item: 281608079; group id 508; item number 1344; lccId None; manufacturer id SMJ Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01918230 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15212
Interchangeable products
Trifluoperazine · DIN 00326836 · $0.2846
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01918230
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 30, 2000 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N05A, N05AB): coverage varies; not interchangeable

  • Fluphenazine (Moditen HCL): general benefit, not a benefit
  • Perphenazine (Trilafon): general benefit, not a benefit
  • Prochlorperazine (Prochlorazine): general benefit, not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE 28:16:08 Tranquilizers

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

PERPHENAZINE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 2mg, 4mg, 8mg, 16mg · Tab

PROCHLORPERAZINE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 5mg, 10mg · Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

Trifluoperazine · DIN 00345539 Shortage status: active shortage (reported 2019-03-15, last updated 2026-05-14); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00345539

Check this DIN again

Trifluoperazine · DIN 00312754 Shortage status: active shortage (reported 2020-07-07, last updated 2026-05-14); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00312754

Check this DIN again

Trifluoperazine · DIN 00312746 Shortage status: active shortage (reported 2023-04-20, last updated 2024-07-02) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00312746

Check this DIN again

Trifluoperazine · DIN 00326836 Shortage status: active shortage (reported not recorded, last updated 2024-07-02) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00326836

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Stelazine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026